{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:41:21Z","timestamp":1726472481511},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ebiom.2016.01.017","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T17:09:33Z","timestamp":1452964173000},"page":"26-39","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Emerging Tools for Stroke Prevention in Atrial Fibrillation"],"prefix":"10.1016","volume":"4","author":[{"given":"Christos","family":"Voukalis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"[European atrial fibrillation trial (EAFT)","key":"10.1016\/j.ebiom.2016.01.017_bb0005"},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-4-1","article-title":"Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality","volume":"4","author":"Abbott","year":"2003","journal-title":"BMC Nephrol."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/europace\/euu353","article-title":"Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists","volume":"17","author":"Abumuaileq","year":"2015","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.017_bb0020","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.clinthera.2014.07.015","article-title":"The impact of heart failure and Left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review","volume":"36","author":"Agarwal","year":"2014","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","article-title":"Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials","volume":"38","author":"Amin","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"issue":"November 2012","key":"10.1016\/j.ebiom.2016.01.017_bb0030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jth.12177","article-title":"The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review","volume":"11","author":"Anandasundaram","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0035","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0040","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2012.10.010","article-title":"Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients","volume":"61","author":"Apostolakis","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2012.10.010","article-title":"Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients","volume":"61","author":"Apostolakis","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0050","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT\u2082R\u2082 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"author":"Atrial fibrillation: management | Guidance and guidelines | NICE","key":"10.1016\/j.ebiom.2016.01.017_bb0055"},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0060","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurjhf\/hfs005","article-title":"Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project","volume":"14","author":"Banerjee","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0070","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u201creal world\u201d atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0075","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","article-title":"Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project","volume":"167","author":"Banerjee","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0080","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.amjmed.2014.05.035","article-title":"Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project","volume":"127","author":"Banerjee","year":"2014","journal-title":"Am. J. Med."},{"issue":"26","key":"10.1016\/j.ebiom.2016.01.017_bb0085","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9211","key":"10.1016\/j.ebiom.2016.01.017_bb0090","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","article-title":"Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study","volume":"355","author":"Berge","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijcard.2015.08.074","article-title":"Net clinical benefit of edoxaban versus no treatment in a \u201creal world\u201d atrial fibrillation population: A modelling analysis based on a nationwide cohort study","volume":"201","author":"Blann","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.017_bb0105","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199203123261103","article-title":"The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites","volume":"326","author":"Broderick","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0110","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1378\/chest.14-2099","article-title":"Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study","volume":"147","author":"Br\u00f8nnum Nielsen","year":"2015","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.ebiom.2016.01.017_bb0115","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur. Heart J."},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.017_bb0120","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0125","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation\u2014developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"issue":"28","key":"10.1016\/j.ebiom.2016.01.017_bb0130","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.017_bb0135","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"issue":"5\u20136","key":"10.1016\/j.ebiom.2016.01.017_bb0140","first-page":"282","article-title":"Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice","volume":"33","author":"Choudhury","year":"2004","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.017_bb0145","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.017_bb0150","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0155","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis\u2014task force on anticoagulants in heart disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.017_bb0160","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1161\/STROKEAHA.106.480566","article-title":"Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations","volume":"38","author":"De Keyser","year":"2007","journal-title":"Stroke"},{"issue":"9872","key":"10.1016\/j.ebiom.2016.01.017_bb0165","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"25","key":"10.1016\/j.ebiom.2016.01.017_bb0170","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","article-title":"Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patient","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.017_bb0175","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.017_bb0180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(13)70101-7","article-title":"Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment","volume":"12","author":"Diener","year":"2013","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.ebiom.2016.01.017_bb0185","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","article-title":"Risk of falls and major bleeds in patients on oral anticoagulation therapy","volume":"125","author":"Donz\u00e9","year":"2012","journal-title":"Am. J. Med."},{"issue":"2 Suppl","key":"10.1016\/j.ebiom.2016.01.017_bb0190","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.017_bb0195","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0200","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0210","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","author":"Fibrillation","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.017_bb0215","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3522","article-title":"Assessment of female sex as a risk Factor in Atrial Fibrillation in Sweden: Nationwide Retrospective Cohort Study","volume":"344","author":"Friberg","year":"2012","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.017_bb0225","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation Cohort Study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.ebiom.2016.01.017_bb0230","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ebiom.2016.01.017_bb0235","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0240","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0245","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am. Heart J."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0250","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.017_bb0255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","article-title":"SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation","volume":"127","author":"Gallego","year":"2014","journal-title":"Am. J. Med."},{"issue":"22","key":"10.1016\/j.ebiom.2016.01.017_bb0260","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.017_bb0265","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0270","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: an overview of current developments","volume":"113","author":"Greinacher","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0275","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1160\/TH13-09-0741","article-title":"Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants","volume":"111","author":"Hankey","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.ebiom.2016.01.017_bb0280","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch. Intern. Med."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.017_bb0285","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.017_bb0290","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"7 Suppl","key":"10.1016\/j.ebiom.2016.01.017_bb0295","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cjca.2013.04.005","article-title":"Stroke prevention in atrial fibrillation patients with chronic kidney disease","volume":"29","author":"Hart","year":"2013","journal-title":"Can. J. Cardiol."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0300","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"issue":"13","key":"10.1016\/j.ebiom.2016.01.017_bb0305","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"issue":"may02 1","key":"10.1016\/j.ebiom.2016.01.017_bb0310","doi-asserted-by":"crossref","first-page":"f2573","DOI":"10.1136\/bmj.f2573","article-title":"Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study","volume":"346","author":"Hippisley-Cox","year":"2013","journal-title":"Bmj"},{"issue":"9689","key":"10.1016\/j.ebiom.2016.01.017_bb0315","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.017_bb0330","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1161\/01.STR.23.9.1237","article-title":"Incidence of stroke in Taiwan","volume":"23","author":"Hu","year":"1992","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0335","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1052-3057(10)80159-4","article-title":"A differential effect of aspirin on prevention of stroke in atrial fibrillation","volume":"3","year":"1993","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"21","key":"10.1016\/j.ebiom.2016.01.017_bb0340","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary","volume":"64","author":"January","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0345","series-title":"Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association","volume":"vol 45","author":"Kernan","year":"2014"},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0350","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1160\/TH11-07-0517","article-title":"Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET\/EHRA Consensus Conference","volume":"106","author":"Kirchhof","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0355","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085310","article-title":"Risk of hemorrhagic stroke in Asian American ethnic groups","volume":"25","author":"Klatsky","year":"2005","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ebiom.2016.01.017_bb0360","doi-asserted-by":"crossref","first-page":"876923","DOI":"10.1155\/2015\/876923","article-title":"Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany","volume":"2015","author":"Krejczy","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0365","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis","volume":"141(2 Suppl)","author":"Lansberg","year":"2012"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000319048","article-title":"Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation","volume":"64","author":"Lee","year":"2010","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0375","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach","volume":"137","author":"Lip","year":"2010","journal-title":"CHEST J."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0380","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrcardio.2011.112","article-title":"The role of aspirin for stroke prevention in atrial fibrillation","volume":"8","author":"Lip","year":"2011","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv431","article-title":"The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history","author":"Lip","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0390","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv415","article-title":"Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors","author":"Lip","year":"2015","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/j.ebiom.2016.01.017_bb0395","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1001\/jama.2015.4369","article-title":"Stroke Prevention in Atrial Fibrillation","volume":"313","author":"Lip","year":"2015","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0400","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.CIR.94.3.425","article-title":"Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. effects of introducing ultra-low-dose warfarin and aspirin","volume":"94","author":"Lip","year":"1996","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0405","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/europace\/eur126","article-title":"Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis","volume":"13","author":"Lip","year":"2011","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0410","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAMe-TT\u2082R\u2082 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation","volume":"146","author":"Lip","year":"2014","journal-title":"Chest"},{"issue":"45","key":"10.1016\/j.ebiom.2016.01.017_bb0415","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on","volume":"35","author":"Lip","year":"2014","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0420","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1160\/TH15-07-0565","article-title":"Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy","volume":"114","author":"Lip","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.017_bb0425","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.159.7.677","article-title":"Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls","volume":"159","author":"Man-Son-Hing","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1477-9560-12-14","article-title":"Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression","volume":"12","author":"Mearns","year":"2014","journal-title":"Thromb. J."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0435","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1161\/STROKEAHA.114.004903","article-title":"Age dependence of risk factors for stroke and death in young patients with atrial fibrillation: a nationwide study","volume":"45","author":"Melgaard","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.ebiom.2016.01.017_bb0440","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex asa risk factor for stroke in atrial fibrillation: a nationwide cohort study","author":"Mikkelsen","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0445","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0450","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0455","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding. CLINICAL PERSPECTIVE","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ebiom.2016.01.017_bb0460","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv476","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","author":"O'Brien","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0465","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide Cohort Study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0470","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a \u201creal world\u201d Nationwide Cohort Study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.017_bb0475","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0480","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH11-12-0827","article-title":"The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation: Results from the national multicentre BNK Online Bridging Registry (BORDER)","volume":"108","author":"Omran","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0485","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1160\/TH13-08-0667","article-title":"Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?","volume":"111","author":"Paciaroni","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0490","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.ebiom.2016.01.017_bb0495","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF Trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0500","article-title":"A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey","volume":"1093-1100","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0505","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and Thromboembolism in Atrial Fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ. J."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0510","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern. Emerg. Med."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0515","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1160\/TH15-03-0192","article-title":"Design and rationale for RE-VERSE AD: A Phase 3 study of idarucizumab, a specific reversal agent for dabigatran","volume":"114","author":"Pollack","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0520","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2013.07.008","article-title":"Novel oral anticoagulants in non-valvular atrial fibrillation","volume":"26","author":"Potpara","year":"2013","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0530","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7326\/0003-4819-116-1-6","article-title":"II. Echocardiographic features of patients at risk. The stroke prevention in atrial fibrillation investigators","volume":"116","author":"Predictors of thromboembolism in atrial fibrillation","year":"1992","journal-title":"Ann. Intern. Med."},{"author":"PubMed \u2013 NCBI","key":"10.1016\/j.ebiom.2016.01.017_bb0535"},{"author":"PubMed \u2013 NCBI","key":"10.1016\/j.ebiom.2016.01.017_bb0540"},{"issue":"19","key":"10.1016\/j.ebiom.2016.01.017_bb0545","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJM200105103441907","article-title":"Spontaneous Intracerebral Hemorrhage","volume":"344","author":"Qureshi","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0550","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"23","key":"10.1016\/j.ebiom.2016.01.017_bb0555","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Rold\u00e1n","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.ebiom.2016.01.017_bb0560","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.amjmed.2015.05.036","article-title":"The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective \u201creal-world\u201d Inception Cohort Study","volume":"128","author":"Rold\u00e1n","year":"2015","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0565","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1160\/TH14-08-0681","article-title":"The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview","volume":"112","author":"Rubboli","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"9921","key":"10.1016\/j.ebiom.2016.01.017_bb0570","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0575","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1160\/TH15-02-0169","article-title":"Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists","volume":"114","author":"Ruiz-Ortiz","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0580","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/oxfordjournals.aje.a009445","article-title":"Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study","volume":"147","author":"Sacco","year":"1998","journal-title":"Am. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0585","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11239-015-1216-4","article-title":"Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves","volume":"40","author":"Schulman","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0590","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ajg.2014.398","article-title":"The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study","volume":"110","author":"Sengupta","year":"2015","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0595","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12360","article-title":"Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation","volume":"278","author":"Shields","year":"2015","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.ebiom.2016.01.017_bb0605","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0610","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1160\/TH14-02-0118","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis","volume":"111","author":"Skj\u00f8th","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.ebiom.2016.01.017_bb0615","first-page":"672","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score","volume":"8","author":"Smith","year":"2012","journal-title":"EuroIntervention J. Eur. Collab. Work Gr. Interv. Cardiol. Eur. Soc. Cardiol."},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0620","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCULATIONAHA.114.011777","article-title":"Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"131","author":"Steinberg","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ebiom.2016.01.017_bb0625","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7326\/0003-4819-116-1-6","article-title":"Predictors of Thromboembolism in Atrial Fibrillation: II. Echocardiographic Features of Patients at Risk","volume":"116","author":"The Stroke Prevention in Atrial Fibrillation Investigators","year":"1992","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.ebiom.2016.01.017_bb0630","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/01.STR.32.8.1732","article-title":"Incidence of the major stroke subtypes: initial findings from the North East Melbourne Stroke Incidence Study (NEMESIS)","volume":"32","author":"Thrift","year":"2001","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.ebiom.2016.01.017_bb0635","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5694\/mja12.10614","article-title":"An update of consensus guidelines for warfarin reversal","volume":"198","author":"Tran","year":"2013","journal-title":"Med. J. Aust."},{"issue":"10","key":"10.1016\/j.ebiom.2016.01.017_bb0640","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ebiom.2016.01.017_bb0645","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/qjmed\/hcu054","article-title":"Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis","volume":"107","author":"Wagstaff","year":"2014","journal-title":"QJM"},{"issue":"2","key":"10.1016\/j.ebiom.2016.01.017_bb0650","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"issue":"9","key":"10.1016\/j.ebiom.2016.01.017_bb0655","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ebiom.2016.01.017_bb0660","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/STROKEAHA.111.636373","article-title":"Fibrin D-dimer, tissue-type plasminogen activator, von Willebrand factor, and risk of incident stroke in older men","volume":"43","author":"Wannamethee","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.ebiom.2016.01.017_bb0665","first-page":"114(5)","article-title":"Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants","author":"Weitz","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"24","key":"10.1016\/j.ebiom.2016.01.017_bb0670","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1001\/jama.2012.6756","article-title":"Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator","volume":"307","author":"Xian","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ebiom.2016.01.017_bb0675","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis","volume":"141(2 Suppl)","author":"You","year":"2012"},{"issue":"7","key":"10.1016\/j.ebiom.2016.01.017_bb0680","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0735-1097(98)00146-6","article-title":"Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators","volume":"31","author":"Zabalgoitia","year":"1998","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396416300135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396416300135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:14:16Z","timestamp":1567538056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396416300135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":135,"alternative-id":["S2352396416300135"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.01.017","relation":{},"ISSN":["2352-3964"],"issn-type":[{"type":"print","value":"2352-3964"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Tools for Stroke Prevention in Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}